« Previous Abstract"Assessment of Occupational Safety and Hygiene Perception among Afro-Caribbean Hair Salon Operators in Manchester, United Kingdom"    Next AbstractA case of flavor-induced lung disease »

Per Med

Title:		Breath biomarkers for personalized medicine
Author(s):		Modak AS;
Address:		"Cambridge Isotope Laboratories Inc., Andover, MA 01810, USA. anilm@isotope.com"
Journal Title:		Per Med
Year:		2010
Volume:		7
Issue:		6
Page Number:		643 - 653
DOI:		10.2217/pme.10.61
ISSN/ISBN:		1744-828X (Electronic) 1741-0541 (Linking)
Abstract:		"Personalized medicine, in the near future, has the potential to revolutionize healthcare by allowing physicians to individualize therapy for patients through the early diagnosis of disease and risk assessment to optimize clinical response with minimal toxicity. The identification of biomarkers could detect, diagnose and help guide therapy to improve survival and quality of life by the early identification of responders to the drugs. Volatile organic compounds and stable isotope-labeled (13)CO(2) in breath can be uniquely utilized as in vivo diagnostic biomarkers of disease and/or lack of enzyme activity to aid physicians to personalize medication. Noninvasive detection of ailments and monitoring therapy by human breath analysis is an emerging field of medical diagnostics representing a rapid, economic and simple alternative to standard invasive blood analysis, endoscopy or harmful imaging techniques such as x-ray and CT scans"
Keywords:		biomarkers breath tests organic compounds personalized medicine volatile;
Notes:		"PubMed-not-MEDLINEModak, Anil S eng England 2010/11/01 Per Med. 2010 Nov; 7(6):643-653. doi: 10.2217/pme.10.61"